China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will ...
SHANGHAI (Reuters) - Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, ...
Eli Lilly’s (NYSE:LLY) weight-loss drug Zepbound (tirzepatide) will remain in short supply through April-end amid increased ...
, opens new tab weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 5%. Lilly said it expects significant production ...
Benzinga - by Vandana Singh, Benzinga Editor. Tuesday, Eli Lilly And Co (NYSE:LLY) reported first-quarter revenue of $8.77 billion, up 26% year over year, marginally missing the consensus of $8.92 ...
Eli Lilly & Co. said Wednesday that two late-stage trials evaluating a 10 mg or 15 mg injection of tirzepatide — the weight-loss drug marketed in the U.S. as Zepbound — reduced the severity of ...
Benzinga - by Vandana Singh, Benzinga Editor. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has determined that there is no substantial evidence supporting a link ...
Eli Lilly (LLY) has reported a better-than-expected first-quarter profit and raised its forward guidance as sales of its popular weight-loss drugs accelerate. The pharmaceutical giant reported ...
Eli Lily’s weight-loss drug tirzepatide has been shown to “significantly” reduce sleep apnoea severity, the US drugs giant said on Wednesday. The firm said phase 3 clinical trials had showed ...